期刊文献+

肺癌切除组织和支气管切缘P^(53)基因突变的研究 被引量:1

The study of P^(53) gene mutations in incisal tissue and bronchial incisal margin of lung cancer
下载PDF
导出
摘要 目的 检测肺癌切除组织和支气管切缘P53基因突变 ,了解肺癌手术切除后的效果及局部复发情况。方法 用PCR -SSCP方法将40例肺癌和10例肺部良性肿瘤手术切除标本的支气管切缘 (切缘病理切片无癌细胞残留 ) ,肺癌组织和正常肺组织中的P53基因突变 ,同时对手术后切缘癌复发及转移情况作了随访。结果 12例 (30 % )肺癌支气管切缘和24例肺癌组织存在P53 基因突变 ,至于正常肺组织和良性病变肺组织未发现P53基因突变。本组研究表明 ,肺癌组织P53基因突变以小细胞癌 (98% )最高 ,次为鳞癌 (70% ) ,腺癌(40% ) ,P53基因突变以TNM分期的 ,Ⅲ期 (71.4 % )最高 ,次为Ⅱ期 (58% ) ,Ⅰ期 (26% ) ,术后3~8个月随访 ,支气管切缘P53阳性中5例(41.6% )发生支气管残端复发 ,肺癌组织中P53 阳性有13例 (54% ) ,通过随访发现有癌复发及转移 ;P53 阴性者有3例 (27 % )发现癌复发。两组复发有显著差异 (P<0.05)。结论 本文通过分子检测支气管切缘P53基因突变 ,对早期预测部份肺癌术后残留复发具有重要临床意义。 Objective To study P53 gene mutations in incisal tissue and bronchial incisal margin of lung cancer. Methods P53 gene mutations of lung cancer (40 cases), lung benign tumor and normal pulmonary tissue were detected by PCR-SSCP. Results Among lung cancer patients, 12 cases had P53 gene mutations in bronchial incisal margin and 24 cases had P53 gene mutations in insical tissue. Lung benign tumor and normal pulmonary tissue had no P53 gene mutations. During the follow-up period, 41.6% of those who had P53 gene mutations in bronchial incisal margins and 54% of those who had P53 gene mutations in incisal tissue had recurrence or metastasis of lung cancer, while only 27% of those who had no gene mutations showed recurrence of lung cancer (p<0,05). Conclusion Detecting P53 gene mutations in incisal tissue and bronchial incisal margin of lung cancer was of high value in predicting prognosis of operation.
出处 《浙江临床医学》 2001年第4期229-230,共2页 Zhejiang Clinical Medical Journal
关键词 肺肿瘤 支气管切缘 P^53基因 基因突变 肺癌 切除组织 Lung cancer Bronchial incisal margin P 53 gene mutation
  • 相关文献

参考文献5

  • 1Levine AJ, perry ME, Chang A, etal. The 1993 walter Hubert Lee-ture: The role f the P53 tumor- suppressorgene in tumorigenes; s. Brj Cancer, 1994,69(3):409~ 416.
  • 2Kamb A,Grusiv NA, Tatiquian SV, et al. A cell Cycle regulator po-tentiallyinvolved in the gemes:s.1995,70(2):403~ 407.
  • 3Brennan JA, Maol, Hruban RH, et al, Molecular assessment of hist-opathologicalstaging in Squamouscell carcinoma of the head and neck.N Engl med, 1995,332(7):429~ 435.
  • 4Mountain CF, Revisions in the intemational Systen for staging of lung cancer,shest, 1997,111(7):1710~ 1717.
  • 5Buccher: G. Tumor markers: clinical meaning and use, in: Brambilla C, BrambillaE(eds). Lung tumors, New York: marcel Dekker Inc.1999,435~ 452.

同被引文献9

  • 1周欣,李龙芸,古力夏提.HnRNP A2/B1与P53在肺癌患者痰中的表达[J].癌症进展,2006,4(2):172-175. 被引量:3
  • 2Luo JC,Zehab R,Anttila S,et al. Detection of senml p53 protein in lung cancer patients. J Occup Med, 1994,36(2) : 155-160.
  • 3Gemba K, Ueoka H, KiuraK, et al. Immunohistochemical detection of mutant p53 protein in small - cell lung cancer: relationship to treatment outcome, Lung Cancer. 2000,29( 1 ) :23 + 31.
  • 4Bennett WP, Hussain SP, Vahakangas KH, et al. Molecular epidemiology of human cancer risk: gene - environment interactions and p53 mutation spectrum in human lung cancer. J Pathol. 1999,187( 1 ) : 8 - 18.
  • 5Sheikh MS, Fomace AJ. Death and decoy receptors and p53 - mediated apoptosis. Leukemia. 2000,14(8) : 1509 - 1513.
  • 6Luo JC, Neugut AI, Garbowski G, et al. Levels of p.53 antigen in the plasma of patients with adenomas and carcinomas of the colon. Cancer Lett. 1995, 91(2) :235- 240.
  • 7Swets JA, Measuring the accuracy of diagnostic systems. Science, 1998, 240(4857) : 1285 - 1293.
  • 8Barbati A, Mariani L, Porpora MG, et al. Serum evaluation of p53 protein in patients with gynaecological cancer. Anticancer Res. 2000, 20 (2A): 1033- 1035.
  • 9古涛,刘永,王伟,王秀英,冯霞,张蓓,王绪.肺癌端粒酶活性、p53突变蛋白及细胞增殖DNA合成期比例相关研究[J].徐州医学院学报,2002,22(1):30-33. 被引量:3

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部